Opthea (ASX: OPT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Opthea Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Opthea (ASX: OPT)
Latest News
Share Gainers
Why Freedom Foods, LiveTiles, Opthea, & Western Areas charged higher today
Share Gainers
Why the Opthea share price skyrocketed 300% higher in August
Share Gainers
Why Afterpay, Bega Cheese, Fisher & Paykel Healthcare, & Opthea shares charged higher
ASX Share Market News
Opthea share price rockets higher on bullish broker report
Speculative
3 exciting small cap ASX shares to buy in September
Share Fallers
Why Bendigo and Adelaide Bank, Genworth Mortgage Insurance, Opthea, & Orocobre dropped lower
Share Gainers
Why iSignthis and Opthea shares are up over 400% in 2019
Share Fallers
Why Crown Resorts, Mirvac, Opthea, & Northern Star shares dropped lower today
52-Week Highs
Why Newcrest and these ASX shares are flying high right now
ASX Share Market News
Here's why the Opthea share price is up 130% today
Share Gainers
Why Althea, Northern Star, Opthea, & Suncorp shares raced higher today
Share Gainers
Why the Opthea share price could zoom higher today
Frequently Asked Questions
-
No, Opthea does not pay shareholder dividends at this time.
-
Opthea Limited listed on the ASX on 18 April 1991.
OPT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Opthea
Opthea Limited (ASX: OPT) is a clinical-stage biopharmaceutical company. Following the failure of its Phase 3 wet age-related macular degeneration (AMD) trials, the company discontinued that program and relaunched in June 2026 with a new focus on OPT-302 as a potential treatment for lymphangioleiomyomatosis (LAM), a rare lung disease.
Shareholders have been asked to approve a proposed name change to Ceryvyn Therapeutics to reflect the new direction.
OPT Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 08 Jul 2026 | $0.01 | $0.00 | 0.00% | 7,777,329 | $0.01 | $0.02 | $0.01 |
| 07 Jul 2026 | $0.01 | $0.00 | 0.00% | 4,723,387 | $0.02 | $0.02 | $0.01 |
| 06 Jul 2026 | $0.02 | $0.00 | 0.00% | 9,873,809 | $0.02 | $0.02 | $0.01 |
| 03 Jul 2026 | $0.01 | $0.00 | 0.00% | 3,708,050 | $0.02 | $0.02 | $0.01 |
| 02 Jul 2026 | $0.02 | $0.00 | 0.00% | 19,796,064 | $0.02 | $0.02 | $0.01 |
